Clarification of didanosine dosages
Eriksson, C.P.
Postgraduate Medicine 96(3): 26
1994
ISSN/ISBN: 0032-5481 PMID: 8072912 Document Number: 427526
Document emailed within 1 workday
Related Documents
Kahn, J. 1993: New developments in the clinical use of didanosine Journal of Acquired Immune Deficiency Syndromes 6(Suppl 1): S47-S50Podzamczer, D.; Ferrer, E.; Gatell, J.M.; Niubo, J.; Dalmau, D.; Leon, A.; Knobel, H.; Polo, C.; Iniguez, D.; Ruiz, I. 2005: Early virological failure with a combination of tenofovir, didanosine and efavirenz Antiviral Therapy 10(1): 171-177
Staszewski, S.; Haberl, A.; Gute, P.; Nisius, G.; Miller, V.; Carlebach, A. 1998: Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users Antiviral Therapy 3(Suppl 4): 55-56
May, D.B.; Drew, R.H.; Yedinak, K.C.; Bartlett, J.A. 1994: Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers PharmacoTherapy 14(5): 509-513
Monno, L.; Cargnel, A.; Soranzo, M.L.; Chirianni, A.; Ferraro, T.; Di Stefano, M.; Angarano, G. 1999: Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. Ai 454-146 Team Antiviral Therapy 4(4): 195-202
Mira, Jé.A.; Lozano, F.; Santos, Jús.; Ramayo, E.; Terrón, A.; Palacios, R.; León, E.M.; Márquez, M.; Macías, J.; Fernández-Palacin, A.; Gómez-Mateos, Jús.; Pineda, J.A. 2004: Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment Antiviral Therapy 9(4): 511-517
Mira, Jé.A.; Lozano, F.; Santos, Jús.; Ramayo, E.; Terrón, A.; Palacios, R.; León, E.M.; Márquez, M.; Macías, J.; Fernández-Palacin, A.; Gómez-Mateos, Jús.; Pineda, J.A. 2004: Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment Antiviral Therapy 9(4): 511-517
Røge, B.T.; Katzenstein, T.L.; Obel, N.; Nielsen, H.; Kirk, O.; Pedersen, C.; Mathiesen, L.; Lundgren, J.; Gerstoft, J. 2003: K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine Antiviral Therapy 8(2): 173-182
Raffi, F.; Reliquet, V.; Ferré, V.; Arvieux, C.; Hascoet, C.; Bellein, V.; Besnier, J.M.; Breux, J.P.; Garré, M.; May, T.; Molina, J.M.; Perré, P.; Raguin, G.; Rozenbaum, W.; Zucman, D. 2000: The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults Antiviral Therapy 5(4): 267-272
Canestri, A.; Sow, P.S.; Vray, M.; Ngom, F.; M'boup, S.; Kane, C.T.; Delaporte, E.; Gueye, M.é; Peytavin, G.; Girard, P.M.; Landman, R. 2007: Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal Medgenmed: Medscape General Medicine 9(4): 7
Tatsunami, S.; Sako, K.; Kuwabara, R.; Yamada, K. 1998: Using Gaussian-like input rate function in the two-compartment model. Formulation and application to analysis of didanosine plasma concentration in two Japanese hemophiliacs International Journal of Clinical Pharmacology Research 18(3): 129-135
Molina, J.M.; Chêuc, G.; Ferchal, F.; Journot, V.; Pellegrin, I.; Sombardier, M.N.; Rancinan, C.; Cotte, L.; Madelaine, I.; Debord, T.; Decazes, J.M. 1999: Results of the ALBi trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients Antiviral Therapy 4(Suppl 3): 71-74
Montaner, J.S.; Rachlis, A.; Beaulieu, R.; Gill, J.; Schlech, W.; Phillips, P.; Auclair, C.; Boulerice, F.; Schindzielorz, A.; Smaldone, L. 1994: Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program Journal of Acquired Immune Deficiency Syndromes 7(9): 924-930
Kurt, T.L. 1978: A clarification of numbers Circulation 57(5): 1031
Haessler, G. 1990: Important clarification Iowa Medicine: Journal of the Iowa Medical Society 80(9): 431
Bernstein, A.E. 1992: A point of clarification Journal of the American Medical Women's Association 47(5): 132 139
Møller, L. 1990: Better dosages of psychopharmaceuticals Sygeplejersken 90(50): 11
Echeverry, Mía.Ladi.Londoño. 2004: Clarification from the Sí-Mujer Foundation Gaceta Medica de Mexico 140(2): 267; Author Reply 267-8
Baum, G.; Frey, M.; Santa Teresa, J. 1991: Clarification of ascites fluid Biotechniques 10(4): 456 458 460
McCarthy, E.G.; Finkel, M.L. 1979: Necessary clarification of "unnecessary surgery" Surgery 85(6): 717